Third Quarter 2013


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K
 
Report of Foreign Private Issuer
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
For the month of November 2013
 
Commission File Number 000-31062
 
Oncolytics Biotech Inc.
 
(Translation of registrant's name into English)
 
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
 
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
 
 
Form 20-F   þ
 
Form 40-F   o
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   o
 
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   o
 
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's “home country”), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

EXPLANATORY NOTE

This report on Form 6-K, the September 30, 2013 Interim Financial Statements, and the September 30, 2013 Management Discussion & Analysis attached hereto as Exhibits 99.1 and 99.2, respectively, are hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 (File No. 333-182260) of Oncolytics Biotech Inc., as amended or supplemented.





EXHIBIT
NUMBER
 
DESCRIPTION
 
 
 
99.1
 
Oncolytics Biotech® Inc. September 30, 2013 Interim Financial Statements
99.2
 
Oncolytics Biotech® Inc. September 30, 2013 Management Discussion & Analysis
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
Oncolytics Biotech Inc.
(Registrant)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:  November 7, 2013
 
By:
 
/s/  Kirk Look
 
Kirk Look
Chief Financial Officer